J Clin Oncol: Can high-risk bowel cancer be reduced to 3 months to reduce neurotoxicity with Osali platinum treatment?

Because oxaliplatin causes cumulative neurotoxicity, patients and health care workers benefit from shorter treatment times without reducing efficacy.
study analyzed data from patients with high-risk stage II colorectal cancer from four studies to identify the optimal duration of complementary two-line chemotherapy.
patients included in the analysis were treated with fluorouracil, folate and oxalipoli (FOLFOX) or capedabin and oxaliplatin (CAPOX) and were randomly assigned to the March or June treatment group.
endpoints were disease-free survival (DFS) and non-poor efficacy in the June group compared to the March group.
a total of 3,273 patients were randomly assigned to the March or June group, of whom 62% were treated with CAPOX and 38% were treated with FOLFOX.
553 DFS events in the March vs June group of the total population of the united States.
5-year DFS rates for the March and June groups were 80.7% and 83.9% (HR 1.17, 80% CI 1.05-1.31, p-0.39), respectively.
result exceeded the non-poor efficiency limit 1.2.
the efficacy of the treatment seemed to depend on the chemotherapy programme in the 3-month vs 6-month group of different treatments in the IDEA III phase analysis, although the interaction test was negative.
patients treated with CAPOX, the HR in the March vs June group was 1.02 (80% CI 0.88-1.17) and the HR treated by FOLFOX was 1.41 (80% CI 1.18-1,68).
In summary, although treatment has not been proven to be effective for 3 months in the general population over 6 months, CAPOX-assisted treatment for 3 months of convenience, reduced toxicity and cost suggests that CapOX therapy in March could be a potential option for patients with high-risk stage II colon cancer if the osaliptin-based chemotherapy program is appropriate.